---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019070"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:48:24.496114+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports Q1 2022 net loss of $18.4M; cash at $294.8M; ASCO presentation on PC14586

## Summary
- Net loss of $18.4M for Q1 2022 vs $11.6M in Q1 2021; R&D spend increased to $11.8M.
- Cash, equivalents and marketable securities totaled $294.8M as of March 31, 2022, down from $314.1M at year-end 2021.
- Initial Phase 1/2 data for PC14586 (p53 Y220C reactivator) selected for oral presentation at ASCO 2022 on June 7.
- Continued advancement of WIP1 inhibitor and p53 mutant pipeline programs.
- Net cash used in operations was $18.0M in Q1 2022 vs $12.9M in Q1 2021.

## SEC filing metadata
- accession: 0001564590-22-019070
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/0001564590-22-019070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/pmvp-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019070
- JSON: https://secwatch.observer/filing/0001564590-22-019070.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.